Biologic therapies for asthma

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 1, 2010, Pages 19-24

  Gruenberg, David ^a   Busse, William ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Asthma; Biologic therapies; Immunomodulators; Monoclonal antibodies

Indexed keywords

ALTRAKINCEPT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CD4 ANTIBODY; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; DACLIZUMAB; ETANERCEPT; GOLIMUNAB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 9; KELIXIMAB; MEDI 528; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; OMALIZUMAB; PASCOLIZUMAB; PITRAKINRA; PREDNISONE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ANAPHYLAXIS; ASTHMA; BASOPHIL; CLINICAL TRIAL; DENDRITIC CELL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; MAST CELL; QUALITY OF LIFE; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC FACTORS; INTERLEUKIN-5; OLIGONUCLEOTIDES; TREATMENT OUTCOME;

EID: 74549121610     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283328398     Document Type: Review

References (35)

1. Ballas ZK. Immunomodulators: a brave new world. J Allergy Clin Immunol 2008; 121:331-333.
2. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372:1073-1087.
3. Nowak D. Management of asthma with antiimmunoglobulin E: a review of clinical trials of omalizumab. Respir Med 2006; 100:1907-1917.
4. Ballow M. Biologic immune modifiers: trials and tribulations: are we there yet? J Allergy Clin Immunol 2006; 118:1209-1215.
5. Holgate S, Buhl R, Bousquet J, et al. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009; 103:1098-1113.
6. Price D. The use of omalizumab in asthma. Prim Care Respir J 2008; 17:62-72.
7. Busse WW, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184-190.
8. Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; doi: 10.1016/j.rmed.2009.05.002.
9. Koop MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2008; 39:271-279.
10. Humbert M, Boulet LP, Niven RM, et al. Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis. Allergy 2009; 64:81-84.
11. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39:788-797.
12. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol 2008; 121:1473-1483.
13. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as antiinterleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167:199-204.
14. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-1071.
15. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
16. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisonedependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
17. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor a in refractory asthma. N Engl J Med 2006; 354:697-708.
18. Erzurum SC. Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 2006; 354:754-758.
19. Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFa) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012-1018.
20. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-a in asthma. Am J Respir Crit Care Med 2006; 174:753-762.
21. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-a blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549-558.
22. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-970.
23. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. Am J Respir Crit Care Med 1999; 160:1816-1823.
24. Steinke JW. Antiinterleukin-4 therapy. Immunol Allergy Clin North Am 2004; 24:599-614.
25. Shames RS, Vexler V, Lane N, et al. The safety and pharmacokinetics of SB240683 (anti-IL-4 humanized monoclonal antibody) in patients with mild to moderate asthma. J Allergy Clin Immunol 2001; 107:S317.
26. Kon OM, Sihra BS, Loh LC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ T-cells in asthma. Eur Respir J 2001; 18:45-52.
27. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-1431.
28. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009; 61:195-204.
29. Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008; 121:288-296.
30. Doherty T, Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 2007; 19:676-680.
31. Holgate ST. The airway epithelium is central to the pathogenesis of asthma. Allergol Int 2008; 57:1-10.
32. Long AA. Immunomodulators in the treatment of asthma. Allergy Asthma Proc 2009; 30:109-119.
33. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008; 178:1002-1008.
34. Nelson H, Yancey S, Emmett A, et al. Incidence of asthma exacerbations by season and the effects of treatment with fluticasone propionate/salmeterol (FSC) or fluticasone propionate (FP) compared with montelukast [abstract]. J Allergy Clin Immunol 2005; 115:S2.
35. Busse WW, Baker JW, Charous BL, et al. Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma [abstract]. J Allergy Clin Immunol 2004; 113:S286-S287.